Market Overview:
The global anticoagulation therapy market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of thromboembolic disorders, increasing geriatric population, and technological advancements in anticoagulant therapies. By type, the NOACs segment is expected to grow at a higher CAGR than the warfarin segment during the forecast period. This growth can be attributed to the benefits offered by NOACs over warfarin such as fewer drug interactions and lower risk of bleeding complications. By application, hospital associated clinics are expected to account for the largest share of the global anticoagulation therapy market in 2018. This large share can be attributed to factors such as rising prevalence of thromboembolic disorders and increasing number of hospital admissions for stroke patients worldwide.
Product Definition:
Anticoagulation therapy is the use of medications to prevent or treat blood clots. It is important because it can help prevent heart attacks, strokes, and other serious problems.
NOACs:
Non-thrombolytic Anti-coagulants (NOACs) are a new class of anticoagulant drugs that differ from warfarin in several ways. NOACs were developed to overcome the limitations of traditional anticoagulants, such as bleeding complications and lack of efficacy in patients with significant renal impairment.
Warfarin:
Anticoagulants are used to prevent blood clotting during surgery or treatment. The most common anticoagulant is warfarin. It is a type of medication that reduces the ability of the blood to coagulate (clot). Other anticoagulants include heparins, vitamin K antagonists, direct thrombin inhibitors and direct factor Xa inhibitors. Anticoagulation therapy may be required for a short period (e.g.
Application Insights:
The independent clinics segment dominated the global anticoagulation therapy market in 2017. This is attributed to factors such as growing preference for self-administration of medications and rising awareness about treatment options among patients. Furthermore, increasing number of clinical trials supporting the use of warfarin for atrial fibrillation will boost product demand over the forecast period.
On the other hand, hospital associated clinics are expected to witness lucrative growth owing to increasing prevalence of Cardiovascular Diseases (CVDs) globally coupled with rising geriatric population across various regions including Europe and North America. Moreover, these facilities offer cost benefits over independent clinics due to economies of scale attained through mergers & acquisitions in recent years.
Regional Analysis:
North America dominated the global anticoagulation therapy market in 2017. This is due to the presence of a large number of international manufacturers and availability of branded drugs at affordable prices. Moreover, high patient awareness levels coupled with favorable government initiatives are some other factors contributing to its largest share. For instance, International Warfarin Day is celebrated on 17th April every year in memory warfarin sodium was first introduced in 1952 by R&D Systems Inc., U.S.
Asia Pacific region is expected to grow at a lucrative rate over the forecast period owing to increasing geriatric population prone toward various chronic diseases along with growing healthcare expenditure levels which require higher spending on treatment procedures like hospitalization or medical care visits/hospital-acquired conditions (HAC).
Growth Factors:
- Increasing incidence of thromboembolic disorders: The global anticoagulation therapy market is expected to grow at a CAGR of 5.5% during the forecast period due to the increasing incidence of thromboembolic disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Growing geriatric population: The global anticoagulation therapy market is also expected to be driven by the growing geriatric population, as this population is more susceptible to developing thromboembolic disorders.
- Technological advancements in anticoagulant drugs: The development of novel oral anticoagulants (NOACs) has revolutionized the treatment landscape for patients with venous and arterial thrombotic conditions, thereby driving growth in the global anticoagulation therapy market. These novel agents are safer and more efficacious than traditional warfarin, offering an improved therapeutic option for patients with coexisting medical conditions. In addition, they are easier to use than warfarin and do not require regular monitoring or dose adjustment, making them an attractive choice for both physicians and patients alike. As a result, NOACs are rapidly gaining popularity across all regions worldwide and are likely to drive significant growth in the global anticoagulation therapy market over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Anticoagulation Therapy Market Research Report
By Type
NOACs, Warfarin
By Application
Hospital Associated Clinics, Independent Clinics, Pharmacy-Based Clinics
By Companies
CH Boehringer Sohn, Bristol-Myers Squibb, Johnson＆Johnson, Pfizer, Daiichi Sankyo, Portola Pharmaceuticals, Roche, Abbott
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Anticoagulation Therapy Market Report Segments:
The global Anticoagulation Therapy market is segmented on the basis of:
Types
NOACs, Warfarin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Associated Clinics, Independent Clinics, Pharmacy-Based Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CH Boehringer Sohn
- Bristol-Myers Squibb
- Johnson＆Johnson
- Pfizer
- Daiichi Sankyo
- Portola Pharmaceuticals
- Roche
- Abbott
Highlights of The Anticoagulation Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NOACs
- Warfarin
- By Application:
- Hospital Associated Clinics
- Independent Clinics
- Pharmacy-Based Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anticoagulation Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anticoagulation therapy is a treatment for blood clotting disorders. It involves the use of medications to prevent clots from forming in the blood.
Some of the major players in the anticoagulation therapy market are CH Boehringer Sohn, Bristol-Myers Squibb, Johnson¯Â¼â€ Johnson, Pfizer, Daiichi Sankyo, Portola Pharmaceuticals, Roche, Abbott.
The anticoagulation therapy market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anticoagulation Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anticoagulation Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anticoagulation Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anticoagulation Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anticoagulation Therapy Market Size & Forecast, 2018-2028
4.5.1 Anticoagulation Therapy Market Size and Y-o-Y Growth
4.5.2 Anticoagulation Therapy Market Absolute $ Opportunity
Chapter 5 Global Anticoagulation Therapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Anticoagulation Therapy Market Size Forecast by Type
5.2.1 NOACs
5.2.2 Warfarin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Anticoagulation Therapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Anticoagulation Therapy Market Size Forecast by Applications
6.2.1 Hospital Associated Clinics
6.2.2 Independent Clinics
6.2.3 Pharmacy-Based Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anticoagulation Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anticoagulation Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anticoagulation Therapy Analysis and Forecast
9.1 Introduction
9.2 North America Anticoagulation Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anticoagulation Therapy Market Size Forecast by Type
9.6.1 NOACs
9.6.2 Warfarin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Anticoagulation Therapy Market Size Forecast by Applications
9.10.1 Hospital Associated Clinics
9.10.2 Independent Clinics
9.10.3 Pharmacy-Based Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Anticoagulation Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe Anticoagulation Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anticoagulation Therapy Market Size Forecast by Type
10.6.1 NOACs
10.6.2 Warfarin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Anticoagulation Therapy Market Size Forecast by Applications
10.10.1 Hospital Associated Clinics
10.10.2 Independent Clinics
10.10.3 Pharmacy-Based Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Anticoagulation Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anticoagulation Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anticoagulation Therapy Market Size Forecast by Type
11.6.1 NOACs
11.6.2 Warfarin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Anticoagulation Therapy Market Size Forecast by Applications
11.10.1 Hospital Associated Clinics
11.10.2 Independent Clinics
11.10.3 Pharmacy-Based Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Anticoagulation Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America Anticoagulation Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anticoagulation Therapy Market Size Forecast by Type
12.6.1 NOACs
12.6.2 Warfarin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Anticoagulation Therapy Market Size Forecast by Applications
12.10.1 Hospital Associated Clinics
12.10.2 Independent Clinics
12.10.3 Pharmacy-Based Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Anticoagulation Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anticoagulation Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anticoagulation Therapy Market Size Forecast by Type
13.6.1 NOACs
13.6.2 Warfarin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Anticoagulation Therapy Market Size Forecast by Applications
13.10.1 Hospital Associated Clinics
13.10.2 Independent Clinics
13.10.3 Pharmacy-Based Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anticoagulation Therapy Market: Competitive Dashboard
14.2 Global Anticoagulation Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CH Boehringer Sohn
14.3.2 Bristol-Myers Squibb
14.3.3 Johnson＆Johnson
14.3.4 Pfizer
14.3.5 Daiichi Sankyo
14.3.6 Portola Pharmaceuticals
14.3.7 Roche
14.3.8 Abbott
